Immupharma PLC Incanthera plc -- Admission to trading on NEX (4137E)
February 28 2020 - 2:03AM
UK Regulatory
TIDMIMM
RNS Number : 4137E
Immupharma PLC
28 February 2020
28 February 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Incanthera plc - Admission to trading on the NEX Exchange Growth
Market
Publication of Admission Document
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a
specialist drug discovery and development company, notes that
further to its announcement on 17 February 2020, Incanthera plc
("Incanthera"), a specialist oncology company, has today been
admitted to the NEX Exchange Growth Market (TIDM: INC) and has
published its Admission Document.
Following Admission to trading, ImmuPharma retains 7,272,740
ordinary shares in Incanthera, representing 11.9% of Incanthera's
enlarged issued ordinary share capital. As for all Incanthera's
major shareholders, ImmuPharma has entered a standard "lock-in"
agreement for these shares, for a period up to 12 months following
Admission.
ImmuPharma also has 7,272,740 warrants at an exercise price of
9.5p pence, being the price at which new shares have been issued in
the Placing accompanying Incanthera's listing ("Issue Price").
In addition, ImmuPharma has entered into a Subscription
Agreement with Incanthera. Under the Subscription Agreement,
ImmuPharma has the right, at any time prior to 31 October 2020, to
subscribe for 2,631,579 new Ordinary Shares in Incanthera at the
Issue Price (an amount of GBP250,000). Should ImmuPharma not
exercise their right to subscribe by 31 October 2020, Incanthera
may serve notice to ImmuPharma requiring exercise within 10
business days
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin/Henry Todd +44 (0) 203 368 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Jean-Louis Dubrule +32 (0) 497 50 84 03
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases
and cancer. The lead program, Lupuzor(TM), is a first-in class
autophagy immunomodulator which is in Phase III for the treatment
of lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
29 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase III trial for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.com .
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
About Incanthera plc
Incanthera plc was formed in 2010 as a spin-out from the
Institute of Cancer Therapeutics at Bradford University and is
targeting the treatment of cancer through a portfolio of unique
technologies. Having successfully commercialised its lead product
in 2017, it is further developing its portfolio of cancer
therapeutics.
For additional information about Incanthera and to access the
Admission Document, please visit www.incanthera.com .
Incanthera's share price can be accessed via the company's
website, as above, or via the investors page on the NEX Exchange
website, www.nexexchange.com.
Incanthera's LEI code: 2138002HEV4UFBOEXQ97 and ISIN number
GB00BGL7YW15.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAXAXAANEEFA
(END) Dow Jones Newswires
February 28, 2020 02:03 ET (07:03 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024